MCID: GST059
MIFTS: 31

Gestational Trophoblastic Tumor

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Gestational Trophoblastic Tumor

MalaCards integrated aliases for Gestational Trophoblastic Tumor:

Name: Gestational Trophoblastic Tumor 53 55
Gestational Trophoblastic Disease 53 73
Gestational Trophoblastic Neoplasms 73
Gestational Trophoblastic Neoplasm 53
Gtn 53

Classifications:



External Ids:

UMLS 73 C2931618

Summaries for Gestational Trophoblastic Tumor

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 59305Disease definitionGestational trophoblastic tumors (GTT) are malignant forms of gestational trophoblastic disease. The tumor always follows pregnancy, most often molar pregnancy (hydatidiform mole; see this term). Four histological subtypes have been described: invasive mole, gestational choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor (see these terms).EpidemiologyExact annual incidence is not known but it is estimated to be about 1/1,000,000 women.Clinical descriptionGTTs occur following hydatidiform moles (see this term) (15% of complete moles and about 3% of partial moles), following spontaneous miscarriage (1/150) or childbirth (1/40,000). Indicative signs are an absence of normalization or a secondary elevation of total serum chorionic gonadotropin (hCG) levels after evacuation of a hydatidiform mole (more than 60% of cases), persistent unexplained metrorrhagia following spontaneous miscarriage or voluntary termination of pregnancy (VTP) (about 30% of cases) and very occasionally, unexplained metrorrhagia in the weeks or months following normal childbirth or ectopic pregnancy (about 10% of cases). Exceptionally, metastasis may be a sign of the disease in women of childbearing age.EtiologyThe etiology of gestational trophoblastic tumors is not known. Identification of a GTT is based on a total serum hCG assay, which is recommended following hydatidiform moles in patients with metrorrhagia persisting for more than six weeks after pregnancy, and in any patient of childbearing age who has metastasis (lung, liver, brain, kidney, vagina) with no known primary tumor.Diagnostic methodsDiagnosis of a post-molar GTT relies on one of the following four criteria: stable hCG levels (variation of less than 10%) with at least four weekly assays over a period of at least three weeks (days 1, 7, 14, 21), increase of at least 10% in hCG with at least three weekly assays over at least two weeks (days 1, 7, 14), persistence of detectable hCG values for more than six months following mole evacuation or based on histological diagnosis of a choriocarcinoma.Differential diagnosisGTTs must not be confused with hydatidiform moles (see this term) and, for choriocarcinomas, with non-gestational choriocarcinomas, which are most often ovarian.Management and treatmentAs soon as the diagnosis is made, staging must be performed to identify frequent metastases. Staging involves endovaginal pelvic color doppler ultrasound, pelvic and cerebral MRI, and abdominal/chest CT. A lung X-ray must be performed to calculate the FIGO 2000 score (International Federation of Obstetrics and Gynecology) in case of lung metastasis on CT. This score makes it possible to distinguish between low-risk GTTs (score of 6 or lower) and high-risk GTTs (score of 7 or higher). Management should be multidisciplinary and must be discussed by a panel of physicians in a specialized center. Low-risk tumors are treated by systemic single-agent chemotherapy, e.g. methotrexate (marketing authorization). High-risk tumors are treated first line with systemic multi-agent chemotherapy. Hysterectomy can of course not be considered for first-line treatment in women who wish to become pregnant, unless there is no option. Placental site trophoblastic tumors and epithelioid trophoblastic tumors are special cases: the FIGO score is not appropriate and total hysterectomy is the standard treatment as these tumors are usually chemo-resistant.PrognosisThe overall recovery rate is around 99%. The prognosis is very closely related to the rapidity of diagnosis, the risk level of the tumor (low or high) and the suitability of treatment.Visit the Orphanet disease page for more resources.

MalaCards based summary : Gestational Trophoblastic Tumor, also known as gestational trophoblastic disease, is related to recurrent hydatidiform mole and trophoblastic neoplasm. An important gene associated with Gestational Trophoblastic Tumor is CGB5 (Chorionic Gonadotropin Subunit Beta 5). The drugs Nitroglycerin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver.

Related Diseases for Gestational Trophoblastic Tumor

Graphical network of the top 20 diseases related to Gestational Trophoblastic Tumor:



Diseases related to Gestational Trophoblastic Tumor

Symptoms & Phenotypes for Gestational Trophoblastic Tumor

Drugs & Therapeutics for Gestational Trophoblastic Tumor

Drugs for Gestational Trophoblastic Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroglycerin Approved, Investigational Phase 4,Phase 2 55-63-0 4510
2
Methotrexate Approved Phase 2, Phase 3,Phase 3 1959-05-2, 59-05-2 126941
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3 68538-85-2
4
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
5
Ribavirin Approved Phase 3 36791-04-5 37542
6
Carboplatin Approved Phase 3,Phase 1 41575-94-4 10339178 498142 38904
7
Captopril Approved Phase 3 62571-86-2 44093
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
9
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
10
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 22916-47-8 4189
11
Cyclophosphamide Approved, Investigational Phase 3,Not Applicable 50-18-0, 6055-19-2 2907
12
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
13
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Palivizumab Approved, Investigational Phase 3 188039-54-5
16
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
17
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
20
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
21
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
22 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8
23
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
24
Mycophenolic acid Approved Phase 3 24280-93-1 446541
25
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
26
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
27
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
28
Polyestradiol phosphate Approved Phase 3 28014-46-2
29
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3 59-30-3 6037
31 Micronutrients Phase 2, Phase 3,Phase 3
32 Folic Acid Antagonists Phase 2, Phase 3,Phase 3
33 Hematinics Phase 2, Phase 3,Phase 3
34 Dermatologic Agents Phase 2, Phase 3,Phase 3,Not Applicable
35 Trace Elements Phase 2, Phase 3,Phase 3
36 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3
37 Vitamin B Complex Phase 2, Phase 3,Phase 3
38 Vitamins Phase 2, Phase 3,Phase 3
39 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
40 Antidotes Phase 2, Phase 3,Phase 3,Not Applicable
41 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
42 Liver Extracts Phase 2, Phase 3,Phase 3,Phase 1
43 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Not Applicable
44 Antimetabolites Phase 2, Phase 3,Phase 3
45 Bone Density Conservation Agents Phase 2, Phase 3,Phase 3
46 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
47 Calcium, Dietary Phase 2, Phase 3,Phase 3,Not Applicable
48 valacyclovir Phase 3
49
Hydroxyitraconazole Phase 3,Not Applicable
50 Alkylating Agents Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole Recruiting NCT01630954 Phase 4
2 Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms Unknown status NCT02606539 Phase 2, Phase 3 Methotrexate plus folinic acid alone
3 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
4 RCT on the Efficacy of Methotrexate for the Prevention of GTD Completed NCT01984099 Phase 3 Methotrexate;Vitamin B Complex
5 Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer Completed NCT00058071 Phase 3 amifostine trihydrate
6 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
7 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
8 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
9 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
10 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
11 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
12 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
13 Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01823315 Phase 3 MTX 1;MTX 2
14 Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
15 Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor Not yet recruiting NCT02639650 Phase 3 Etoposide;actinomycin D;methotrexate;vincristine;cyclophosphamide;Paclitaxel;Cisplatin;Carboplatin
16 Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia Not yet recruiting NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
17 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia Completed NCT00003688 Phase 2
20 A Trial for Patients With Gestational Trophoblastic Disease Completed NCT00190918 Phase 2 Pemetrexed
21 Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors Completed NCT00521118 Phase 2
22 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
23 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
24 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
25 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
26 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
27 Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
28 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
29 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
30 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
31 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00002673 Phase 2
34 Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias Recruiting NCT03135769 Phase 2 Avelumab administration at 10mg/kg
35 Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Recruiting NCT02664961 Phase 2 TRC105;Bevacizumab
36 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
37 Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy Terminated NCT00096187 Phase 2 pemetrexed disodium
38 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
39 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
40 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
41 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors Completed NCT00003107 Phase 1
42 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1 cefepime hydrochloride
43 Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
44 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1 carboplatin;etoposide;ifosfamide
45 Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant Completed NCT00569283 Phase 1
46 Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy Completed NCT00509691 Phase 1
47 Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant Completed NCT00361049 Phase 1
48 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Suspended NCT02890758 Phase 1
49 Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease Unknown status NCT00166790 chemotherapy agents
50 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177

Search NIH Clinical Center for Gestational Trophoblastic Tumor

Genetic Tests for Gestational Trophoblastic Tumor

Anatomical Context for Gestational Trophoblastic Tumor

MalaCards organs/tissues related to Gestational Trophoblastic Tumor:

41
Bone, Bone Marrow, Liver, Brain, Lung, Kidney, Breast

Publications for Gestational Trophoblastic Tumor

Articles related to Gestational Trophoblastic Tumor:

(show top 50) (show all 184)
# Title Authors Year
1
Pulmonary Arteriovenous Malformation After Metastatic Gestational Trophoblastic Tumor. ( 29884426 )
2018
2
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. ( 27362903 )
2017
3
PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes. ( 28060141 )
2017
4
SALL4 expression in gestational trophoblastic tumors: a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor. ( 27068524 )
2016
5
Gestational Trophoblastic Disease and Choriocarcinoma. ( 26366695 )
2015
6
An investigative study into psychological and fertility sequelae of gestational trophoblastic disease: the impact on patients' perceived fertility, anxiety and depression. ( 26030770 )
2015
7
BEP for high-risk gestational trophoblastic tumor: results from a cohort of 45 patients. ( 26775361 )
2015
8
A rare case of bilateral ectopic pregnancy and differential diagnosis of gestational trophoblastic disease. ( 25717436 )
2015
9
Differential expression patterns of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) -1, -4, -5, and -14 in human placenta and gestational trophoblastic diseases. ( 24786121 )
2014
10
Proportion hyperglycosylated hCG: a new test for discriminating gestational trophoblastic diseases. ( 25275660 )
2014
11
Aberrant expression of E-cadherin and integrin I^-1 in trophoblasts is associated with malignant gestational trophoblastic diseases. ( 23455756 )
2013
12
IFPA Meeting 2012 Workshop Report III: trophoblast deportation, gestational trophoblastic disease, placental insufficiency and fetal growth restriction, trophoblast over-invasion and accreta-related pathologies, placental thrombosis and fibrinolysis. ( 23257209 )
2013
13
The diagnostic value of p27 in comparison to p57 in differentiation between different gestational trophoblastic diseases. ( 23438793 )
2013
14
Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion. ( 23089140 )
2012
15
Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic disease. ( 22659292 )
2012
16
[Expressions of NF-I_Bp65 and II_BI+ in gestational trophoblastic disease and clinical significance]. ( 23046941 )
2012
17
[Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease]. ( 22041443 )
2011
18
Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. ( 21102414 )
2011
19
Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. ( 21522146 )
2011
20
Current issues in the histopathology of gestational trophoblastic tumors. ( 20055562 )
2010
21
Sonographic appearance of gestational trophoblastic disease evolving into epithelioid trophoblastic tumor. ( 20069561 )
2010
22
Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease. ( 19836147 )
2010
23
p21-Activated kinase-1 promotes aggressive phenotype, cell proliferation, and invasion in gestational trophoblastic disease. ( 20413688 )
2010
24
Endothelial nitric oxide synthase expression in gestational trophoblastic diseases. ( 20375793 )
2010
25
Genetic variation in TGF-beta 1 gene promoter and risk of gestational trophoblastic disease. ( 20506678 )
2010
26
Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. ( 20795340 )
2010
27
Overexpression of the Parkinson disease protein DJ-1 and its regulator PTEN in gestational trophoblastic disease. ( 20736773 )
2010
28
Prevalence of gestational trophoblastic disease in ectopic pregnancy. ( 22439057 )
2010
29
P63 expression in gestational trophoblastic disease: correlation with proliferation and apoptotic dynamics. ( 19188816 )
2009
30
Expression of laminin receptor 1 in gestational trophoblastic diseases and normal placenta and its relationship with the development of postmolar tumors. ( 19481788 )
2009
31
PDCD1, CTLA-4 and p53 gene polymorphism and susceptibility to gestational trophoblastic diseases. ( 19263877 )
2009
32
Expression pattern alterations of the serine protease HtrA1 in normal human placental tissues and in gestational trophoblastic diseases. ( 19688690 )
2009
33
Investigation of soluble HER2 and transforming growth factor Beta-1 serum levels in gestational trophoblastic disease. ( 18975137 )
2009
34
Gestational trophoblastic tumor with liver metastasis after misoprostol abortion. ( 18762963 )
2009
35
Oct4 is epigenetically regulated by methylation in normal placenta and gestational trophoblastic disease. ( 18440631 )
2008
36
Clinical value of tumor markers in gestational trophoblastic diseases. ( 19160651 )
2008
37
Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. ( 18772339 )
2008
38
Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches. ( 19004406 )
2008
39
Practical issues in the management of low-risk gestational trophoblast tumors. ( 19004403 )
2008
40
Activated Stat3 expression in gestational trophoblastic disease: correlation with clinicopathological parameters and apoptotic indices. ( 18752497 )
2008
41
Interleukin-18 gene promoter polymorphisms in women with gestational trophoblastic diseases. ( 19097518 )
2008
42
P57kip2 immunohistochemical expression and ultrastructural findings of gestational trophoblastic disease and related disorders. ( 17572845 )
2007
43
[MMP-2/TIMP-2 expression in the trophoblasts of patients with gestational trophoblastic disease]. ( 17355922 )
2007
44
Recurrent gestational trophoblastic disease following persistently normal HCG titers: a rare occurrence. ( 17278903 )
2007
45
Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor. ( 17977170 )
2007
46
Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. ( 17462723 )
2007
47
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease. ( 17163397 )
2007
48
Gestational trophoblastic disease. ( 17304028 )
2007
49
[Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. ( 17336125 )
2007
50
Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. ( 16631920 )
2006

Variations for Gestational Trophoblastic Tumor

Expression for Gestational Trophoblastic Tumor

Search GEO for disease gene expression data for Gestational Trophoblastic Tumor.

Pathways for Gestational Trophoblastic Tumor

GO Terms for Gestational Trophoblastic Tumor

Sources for Gestational Trophoblastic Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....